Divis Laboratories Ltd Share Price
(DIVISLAB)
₹6026.5▲0.23%
as on 05:02PM, 28 Apr 2025
Divis' Laboratories Performance
Day's Low
Day's High
₹5,992Day's Price Range₹6,12552 Week's Low
52 Week's High
₹3,72452-Week Price Range₹6,308.5
| Returns % | |
| 1 Month Return | + 8.34 % |
| 3 Month Return | + 6.98 % |
| 1 Year Return | + 50.72 % |
| Market Stats | |
| Previous Close | ₹6,012.50 |
| Open | ₹6,015.00 |
| Volume | 3.17L |
| Upper Circuit | ₹6,613.50 |
| Lower Circuit | ₹5,411.50 |
| Market Cap | ₹1,59,612.98Cr |
Divis' Laboratories Fundamentals
P/E Ratio
77.23
PEG Ratio
3
Market Cap
₹1,59,612.98 Cr
P/B Ratio
6.75
EPS
60.38
Dividend Yield
0.87
Sector
Pharmaceuticals
ROE
12.04
Mutual Fund Holdings of Divis' Laboratories
Divis' Laboratories Analyst Rating
based on 29 analysts
35.71%
Buy
21.43%
Hold
42.86%
Sell
Based on 29 analysts offering long term price targets for Divis' Laboratories. An average target of ₹5911.86
Source: S&P Global Market Intelligence
Divis' Laboratories Share analysis
Divis' Laboratories price forecast by 29 analysts
Downside of
High
₹7400
Target
₹5911.86
Low
₹4118
Divis' Laboratories target price ₹5911.86, a slight downside of -1.67% compared to current price of ₹6026.5. According to 29 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Divis' Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:63.88%
Forecast
Actual
Including amortisation and stock based compensations
Divis' Laboratories EPS growth forecast
EPS estimate Q1, FY2027:104.77%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Divis Laboratories Ltd
Citigroup Initiates Buy Rating on Divis Laboratories - 25 Apr, 2025
Citigroup has assigned a buy rating to Divis Laboratories with a target price of Rs 7,050. Analysts highlight the company's potential as a primary supplier due to capacity expansion and the upcoming addition of Orforglipron in its pipeline. The stock is considered a top pick in the pharma sector.Divis Laboratories Gains on Positive Brokerage Ratings - 24 Apr, 2025
Divis Laboratories saw significant stock gains after Citi raised its price target to ₹7,050, highlighting strong growth potential in GLP-1 products. Despite some caution from analysts, the overall sentiment remains positive as the company expands its capacity and product pipeline.Divis Labs Secures Long-Term Pharma Supply Agreement - 18 Apr, 2025
Divis Laboratories has entered a long-term manufacturing and supply agreement with a global pharmaceutical company, focusing on advanced intermediates. The company plans to invest ₹650-700 crore for capacity expansion, expecting significant revenue contributions from this partnership.Divis Laboratories Shares Drop Amid Tariff Concerns - 04 Apr, 2025
Divis Laboratories shares fell over 6% to ₹5,410.60 following U.S. President Trump's comments on potential tariffs on pharmaceutical imports, raising investor concerns. The stock's decline reflects fears of increased manufacturing costs and policy risks for companies exporting to the U.S.Divis Laboratories Shares Rise on Positive Recommendations - 03 Apr, 2025
Divis Laboratories shares saw a 1.90% increase following tariff exemptions for pharmaceuticals. SBI Securities recommends buying with targets of Rs 5,830 and Rs 5,900.Divis Labs Positioned for Growth Amid Industry Challenges - 01 Apr, 2025
Divis Laboratories is poised for continued success with a strong growth trajectory, debt-free balance sheet, and strategic expansions. The ramp-up of its Kakinada facility is expected to enhance margins, with a price target of Rs 7,008 anticipated in 8 to 10 months.Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.Divis Laboratories Excluded from Index, Faces Volatility - 28 Mar, 2025
Divis Laboratories has faced a volatile market since its exclusion from the index in September 2024, as noted in recent reports.
Insights on Divis Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 430.0 Cr → 589.0 Cr (in ₹), with an average increase of 14.6% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 11.89% to 12.83% in Mar 2025 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 17.99% to 18.01% in Mar 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 3 months, DIVISLAB stock has moved up by 11.1%
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 132.6% return, outperforming this stock by 100.9%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.89% of holdings in Mar 2025 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 9.59% to 9.39% in Mar 2025 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 2.44K Cr → 2.40K Cr (in ₹), with an average decrease of 1.8% per quarter
Divis' Laboratories News
Dixon and Tata Electronics to Boost Electronics Manufacturing in India
According to sources, Tata Electronics is likely to invest Rs 2,000 crore for electronics components manufacturing under the Rs 23,000 crore incentive scheme launched by the government. Tata Electronics declined to comment on the query sent in this regard.27 Apr, 2025 07:38 PMICICI Securities Recommends Reduce for Tata Elxsi with Target Price of Rs 4250
ICICI Securities has raised Tata Elxsi to Reduce from sell with a revised target price of Rs 4250 (Rs 4,300 earlier). The current market price of Tata Elxsi is Rs 5413.25. Tata Elxsi key products/revenue segments include Software Development Charges and Traded Goods for the year ending 31-Mar-2024. For the quarter ended 31-03-2025, the company has reported a Standalone Total Income of Rs 951.41 crore, down -2.82% from last quarter Total Income of Rs 979.02 crore and up 1.25% from last year same quarter Total Income of Rs 939.63 crore. The company has reported net profit after tax of Rs 172.42 crore in the latest quarter. Tata Elxsi (TELX) has reported a muted Q4FY25 print with revenue contraction of 5.3% QoQ CC, roughly in line with our estimate (of -5.9%) and falling below consensus. Transportation vertical downturn was sharp, though already built into ISec’s estimate. Other highlights of Q4 include: 1) 3 large deals signed with higher annuity component, 2) a pivot towards emerging geographies 3) company highlighting growth bounce back in Q1FY26. Though new deals give some near-term respite, structural and macroeconomic issues loom large. ICICI Securities largely maintains its estimates and tweak FY26E EPS by 130bps on slightly better near-term visibility lent by large deals and optimism in healthcare-led demand.23 Apr, 2025 08:51 AMBanking Stocks Rally Expected with Strong Earnings Growth
the likes of LTTS , likes of LTI or even for that matter Tata Technology, Tata Elxsi , KPIT kind of companies have already shown good amount of order inflow in them and they are seeing the higher amount of profit margin, they are talking about higher amount of profit margin also in subsequent quarters to order inflows.22 Apr, 2025 12:12 PMDivis' Laboratories Financials
Divis' Laboratories Index Inclusions
Divis' Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.89% | 0.00 | |
| Foreign Institutions | 18.01% | 0.00 | |
| Mutual Funds | 12.83% | 0.00 | |
| Retail Investors | 9.39% | 0.00 | |
| Others | 7.88% | 0.00 |
Divis' Laboratories Key Indicators
Divis' Laboratories Valuation
Divis' Laboratories in the last 5 years
Lowest (28.97x)
November 21, 2022
Industry (55.10x)
April 25, 2025
Today (77.23x)
April 25, 2025
Highest (90.48x)
December 4, 2024
Divis' Laboratories Earnings and Dividends
Divis Laboratories Ltd Earnings Results
Divis Laboratories Ltd’s net profit jumped 64.53% since last year same period to ₹589Cr in the Q3 2024-2025. On a quarterly growth basis, Divis Laboratories Ltd has generated 15.49% jump in its net profits since last 3-months.
Read More about Earnings ResultsDivis Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Divis Laboratories Ltd has declared dividend of ₹30 - translating a dividend yield of 0.50%.
Read More about Dividends
Divis' Laboratories Technicals Summary
Bearish
Neutral
Bullish
Divis Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
Divis' Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,59,612.98 Cr | 30.74% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,614.17 Cr | 33.53% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹37,440.71 Cr | -2.29% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,855.08 Cr | -4.09% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,23,234.30 Cr | 31.18% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Divis' Laboratories
Divis Laboratories Ltd's top products include APIs and intermediates for anti-infectives, cardiovascular, central nervous system, anti-diabetics, gastro-intestinal and anti-inflammatory treatments. The company is also a leader in the manufacture of custom synthesis and process development services for the global pharmaceutical industry.
Divis Laboratories Ltd is the proud owner of several popular brands, including Divis Life, Divis Pharma and Divis Health. Divis Life offers a range of health and wellness products, while Divis Pharma provides a wide range of APIs, intermediates and custom synthesis services.
Revenue: ₹2,319.00Cr as on December 2024 (Q4 24)
Net Profit: ₹589.00Cr as on December 2024 (Q4 24)
Listing date: 12 Mar, 2003
Chairperson Name: Ramesh B V Nimmagadda
| Organisation | Divis' Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Divis Laboratories Ltd
What is Divis Laboratories Ltd price today?
Divis Laboratories Ltd share price today stands at ₹6026.5, Open: ₹6015, Previous Close: ₹6012.5, High: ₹6125, Low: ₹5992, 52 Week High: ₹6308.5, 52 Week Low: ₹3724.
How to Buy Divis Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Divis Laboratories Ltd shares
What are today's traded volumes of Divis Laboratories Ltd?
Today's traded volume of Divis Laboratories Ltd(DIVISLAB) is 3.17L.
What is today's market capitalisation of Divis Laboratories Ltd?
Today's market capitalisation of Divis Laboratories Ltd(DIVISLAB) is ₹159612.98Cr.
What is the 52 Week High and Low Range of Divis Laboratories Ltd?
How much percentage Divis Laboratories Ltd is down from its 52 Week High?
Divis Laboratories Ltd (DIVISLAB) share price is ₹6026.5. It is down -4.47% from its 52 Week High price of ₹6308.5
How much percentage Divis Laboratories Ltd is up from its 52 Week low?
Divis Laboratories Ltd (DIVISLAB) share price is ₹6026.5. It is up 61.83% from its 52 Week Low price of ₹3724